Asset
MONALIZUMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02557516 | phase1_2 | terminated | 2015-11-09 | 2018-10-29 | Innate Pharma | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL |
| NCT02331875 | phase1_2 | terminated | 2014-12-01 | 2016-12-01 | Innate Pharma | Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity |
| NCT02643550 | phase1_2 | completed | 2015-12-01 | 2023-03-28 | Innate Pharma | Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
FDA applications (0)
This company has no applications containing this asset.